| Name | : | damon987 |
| Website | : | Visit Website |
| Blog | : | Visit Blog |
| Social Links | : |
Clinical trials form an integral part of the overall drug development process, enabling the necessary evaluation of the safety and efficacy of a drug candidate. Studies suggest that around 40% of the total investment made for the development of drug candidate is dedicated to clinical trials; this is equivalent to an expenditure of USD 78 billion annually.
Since the approval of Orthoclone OKT3? in 1986, monoclonal antibodies have become an important part of modern healthcare practices. In fact, several experts consider monoclonal antibodies to be the backbone of the biopharmaceutical industry. It is worth noting that, till date, more than 100 therapeutic monoclonal antibodies have been approved across different geographies
According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85% this is believed to prevent close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles.
Amongst various efforts to ensure efficient drug delivery, subcutaneous administration has emerged as one of the most promising approaches to deliver viscous biologic drugs in a patient friendly format. Owing to its numerous compelling advantages, the concept has gained huge traction in recent years.
In today?s pharmaceutical market, many drugs are supplied in powdered formulation because of their lower shelf life in liquid formulation. The drugs are formulated into powdered form by various processes such as lyophilisation or spray drying; these drugs are then reformulated into liquid form by mixing with a suitable diluent at the time of administration.
Primary packaging, such as vials, syringes, and cartridges, and their affiliated closures, play a vital role in ensuring the stability, and sterility, and thereby, the overall quality, efficacy and safety of a drug product. Moreover, the packaging bears the product label, which provides information related to the drug and, in certain cases, dosing instructions
Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications.
Clinical trials form an integral part of the overall drug development process, enabling the necessary evaluation of the safety and efficacy of a drug candidate. Studies suggest that around 40% of the total investment made for the development of drug candidate is dedicated to clinical trials; this is equivalent to an expenditure of USD 78 billion annually.
It is a well-known fact that development of a novel therapeutic intervention is both a time and cost intensive process. In fact, several reports have indicated that it can take around 10 years for a prescription medicine to transition from the discovery stage to the market, requiring investments worth over USD 2.5 billion.
Avastin? (bevacizumab) is VEGF-A targeting, humanized monoclonal antibody-based therapeutic developed by Genentech and Roche. It was the first angiogenesis inhibitor drug to be approved by the US FDA. Avastin? was first approved for treatment of advanced colon cancer (2004); since then, the drug has been approved for advanced lung cancers (2006), metastatic breast cancers (2008), kidney cancers and brain (glioblastoma) cancers (2009).
Irene Kosse
Steves Ultimate Air
Classy Wig & Hair
Deluxe Painting Services
Teeth Talk Dentistry
Betpassioncoi
Yg88 Appcom
R666 Com
Aw8
Wichita Falls Water Damage Restoration Pros